Glemanserin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Glemanserin
Glemanserin structure.png
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H25NO
Molar mass295.419 g/mol g·mol−1
3D model (JSmol)

Glemanserin (INN) (developmental code name MDL-11,939) is a drug which acts as a potent and selective 5-HT2A receptor antagonist.[1] The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue.[2] Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder.[3] However, it was ultimately found to be ineffective and was not marketed.[3]

See also[edit]

References[edit]

  1. ^ Mark W. Dudley; Norbert L. Wiech; Francis P. Miller; et al. (1988). "Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT2 receptors". Drug Development Research. 13 (1): 29–43. doi:10.1002/ddr.430130104.
  2. ^ Berend Olivier (10 July 1997). Serotonin Receptors and Their Ligands. Elsevier. p. 167. ISBN 978-0-444-82041-9. Retrieved 6 May 2012.
  3. ^ a b Sramek JJ, Robinson RE, Suri A, Cutler NR (February 1995). "Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder". Journal of Clinical Psychopharmacology. 15 (1): 20–2. doi:10.1097/00004714-199502000-00004. PMID 7714223.